Janus Henderson Group PLC Grows Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Janus Henderson Group PLC lifted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1,308.1% during the first quarter, HoldingsChannel.com reports. The fund owned 109,552 shares of the specialty pharmaceutical company’s stock after buying an additional 101,772 shares during the quarter. Janus Henderson Group PLC’s holdings in ANI Pharmaceuticals were worth $8,425,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the 1st quarter worth $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after buying an additional 423 shares during the period. Jane Street Group LLC purchased a new position in shares of ANI Pharmaceuticals during the first quarter valued at $2,706,000. Finally, Norges Bank bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $625,000. Institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 2,772 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total value of $220,374.00. Following the completion of the transaction, the senior vice president owned 78,696 shares of the company’s stock, valued at approximately $6,256,332. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the sale, the director directly owned 38,432 shares in the company, valued at $3,098,772.16. This trade represents a 20.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 88,029 shares of company stock worth $6,954,472 over the last ninety days. 8.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of research reports. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Guggenheim reaffirmed a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Canaccord Genuity Group began coverage on shares of ANI Pharmaceuticals in a report on Thursday, July 16th. They set a “hold” rating and a $91.00 price objective on the stock. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $105.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $79.88 on Thursday. ANI Pharmaceuticals, Inc. has a 12 month low of $64.99 and a 12 month high of $99.50. The stock has a fifty day moving average price of $80.99 and a 200-day moving average price of $79.39. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The firm has a market cap of $1.82 billion, a PE ratio of 20.22 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm’s quarterly revenue was up 20.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.